BC Extra | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

Keen to take advantage of the rising importance of autophagy, Merck has acquired Avalon Ventures-backed Calporta for up to $576 million. Based on research from the University of Michigan, Calporta has preclinical compounds against TRPML1,...
BC Innovations | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases. According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared...
BC Innovations | Jun 4, 2019
Distillery Therapeutics

TRPML1 agonists for H. pylori infections

DISEASE CATEGORY: Infectious disease INDICATION: Helicobacter Cell culture and organoid studies suggest agonizing TRPML1 could help treat Helicobacter pylori infection. In mouse gastric organoids or a human gastric epithelium cell line infected with H. pylori...
BC Innovations | Aug 17, 2017

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Mucolipin 1 (TRPML1; MCOLN1); inositol polyphosphate-5-phosphatase f (INPP5F)

Renal disease INDICATION: Renal damage; renal failure Patient sample and cell culture studies suggest enhancing TRPML1 activity could help treat renal damage and failure associated with Lowe syndrome, which is caused by mutations in INPP5F...
BC Week In Review | Jun 22, 2015
Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

Avalon Ventures and GlaxoSmithKline launched three build-to-buy companies, Adrenergics, CadheRx and Calporta, each with $3 million in series A funding and $7 million in R&D support. The companies will be housed at Avalon’s COI Pharmaceuticals...
BioCentury | Jun 22, 2015

Build-to-buy basket

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC. The newest cohort of companies includes Adrenergics Inc....
BC Extra | Jun 16, 2015
Financial News

Avalon, GSK launch three more biotechs

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched three build-to-buy companies, each with $3 million in series A funding and $7 million in R&D support. Adrenergics Inc. is focused on therapies for dilated cardiomyopathy. CadheRx...
BC Innovations | Oct 16, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy Mucolipin 1 (MCOLN1; ML4) Mouse studies suggest enhancing ML4 activity could help treat muscular dystrophies. In mice, knockout of Ml4 decreased muscle...
BC Innovations | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Metabolic disease Metabolic disorders Mucolipin 1 (TRPML1; MCOLN1) Studies in cell culture suggest that targeting TRPML1 could help treat mucolipidosis type...
Items per page:
1 - 10 of 10